Get the Stockscreener App
14.52
3.01%
-0.45
After Hours:
14.46
-0.06
-0.41%
Amarin Corp Adr stock is traded at $14.52, with a volume of 54,181.
It is down -3.01% in the last 24 hours and down -10.48% over the past month.
Amarin Corp PLC is a biopharmaceutical company. It is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa.
See More
Previous Close:
$14.97
Open:
$15
24h Volume:
54,181
Relative Volume:
0.48
Market Cap:
$300.67M
Revenue:
$306.91M
Net Income/Loss:
$-59.11M
P/E Ratio:
-96.80
EPS:
-0.15
Net Cash Flow:
$6.35M
1W Performance:
-6.32%
1M Performance:
-10.48%
6M Performance:
+25.95%
1Y Performance:
+6.45%
1-Day Range:
$14.37
$15.07
1-Week Range:
$14.37
$15.61
52-Week Range:
$7.08
$17.49
Amarin Corp Adr Stock (AMRN) Company Profile
Name
Amarin Corp Adr
Sector
Industry
Phone
353 1 6699 020
Address
SPACES SOUTH DOCKLANDS, BLOCK C, DUBLIN 2
Compare AMRN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AMRN
Amarin Corp Adr
|
14.52 | 309.98M | 306.91M | -59.11M | 6.35M | -0.15 |
|
LLY
Lilly Eli Co
|
740.07 | 682.35B | 49.00B | 11.11B | -1.27B | 12.29 |
|
JNJ
Johnson Johnson
|
164.74 | 402.82B | 90.63B | 22.66B | 16.40B | 9.35 |
|
ABBV
Abbvie Inc
|
189.02 | 334.40B | 57.37B | 4.20B | 15.39B | 2.35 |
|
NVS
Novartis Ag Adr
|
113.74 | 225.78B | 55.19B | 13.65B | 16.81B | 6.86 |
|
MRK
Merck Co Inc
|
78.12 | 205.28B | 63.62B | 16.41B | 17.04B | 6.49 |
Amarin Corp Adr Stock (AMRN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-20-23 | Resumed | JP Morgan | Underweight |
| Oct-25-23 | Downgrade | Jefferies | Buy → Hold |
| Jan-06-23 | Upgrade | Jefferies | Hold → Buy |
| May-06-22 | Downgrade | JP Morgan | Neutral → Underweight |
| May-05-22 | Downgrade | H.C. Wainwright | Buy → Neutral |
| May-05-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| May-04-22 | Downgrade | Northland Capital | Outperform → Market Perform |
| May-12-21 | Downgrade | Goldman | Neutral → Sell |
| Sep-29-20 | Resumed | JP Morgan | Neutral |
| Aug-26-20 | Initiated | Piper Sandler | Overweight |
| May-05-20 | Initiated | Northland Capital | Outperform |
| Mar-31-20 | Downgrade | Goldman | Buy → Neutral |
| Mar-31-20 | Downgrade | Jefferies | Buy → Hold |
| Mar-31-20 | Upgrade | Oppenheimer | Underperform → Perform |
| Mar-13-20 | Upgrade | Goldman | Neutral → Buy |
| Mar-02-20 | Initiated | Cowen | Outperform |
| Feb-18-20 | Upgrade | Citigroup | Neutral → Buy |
| Jan-06-20 | Initiated | JP Morgan | Neutral |
| Dec-16-19 | Downgrade | Stifel | Buy → Hold |
| Nov-20-19 | Initiated | Oppenheimer | Underperform |
| Nov-18-19 | Downgrade | Citigroup | Buy → Neutral |
| Nov-15-19 | Reiterated | SVB Leerink | Outperform |
| Oct-31-19 | Initiated | Aegis Capital | Buy |
| Oct-15-19 | Initiated | Goldman | Neutral |
| Aug-14-19 | Initiated | SVB Leerink | Outperform |
| Jul-09-19 | Reiterated | Jefferies | Buy |
| Jun-17-19 | Initiated | ROTH Capital | Buy |
| Mar-22-19 | Initiated | Stifel | Buy |
View All
Amarin Corp Adr Stock (AMRN) Latest News
Amarin's Q2 Earnings & Revenues Trump Estimates, Stock Rises - Barchart.com
Amarin Gears Up To Report Q2 Earnings: Here's What To Expect - Barchart.com
VKTX Stock Down On Wider-Than-Expected Loss In Q2, Nil Sales - Barchart.com
Zacks.com featured highlights include Mama's Creations, Bassett Furniture Industries and Amarin - Barchart.com
KRYS Begins Dosing With Gene Therapy In Rare Eye Disease, Stock Up - Barchart.com
RYTM Stock Rises On Upbeat Acquired Hypothalamic Obesity Study Data - Barchart.com
PROK Surges More Than 500% On Upbeat Data From Kidney Cell Therapy Study - Barchart.com
Amarin Soars 27% on Vazkepa Licensing Deal With Recordati in the EU - Yahoo Finance
Amarin licenses VAZKEPA to Recordati in 59 European countries - Investing.com
Is Amarin (AMRN) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
KURA Stock Rises More Than 15% This Past Week: Here's Why - Barchart.com
Is GSK PLC Sponsored ADR (GSK) Outperforming Other Medical Stocks This Year? - Yahoo Finance
RCKT Stock Tanks On Patient Death In Danon Disease Study - Barchart.com
SpringWorks Gets CHMP Nod For Mirdametinib In Rare Disease - Barchart.com
Amarin's Q1 Earnings Beat Estimates, Revenues Decline Y/Y - Barchart.com
Amarin earnings beat by $0.04, revenue topped estimates - Investing.com
Amarin to Report First Quarter 2025 Financial Results and Host Conference Call on May 7, 2025 - Barchart.com
Press Release Distribution & PR Platform - ACCESS Newswire
Looking For A Top Momentum Stock? Check Out Amarin Corp ADR (NASDAQ: AMRN) - Stocksregister
Amarin Takes Critical Step to Avoid Nasdaq Delisting with 1-for-20 Share Consolidation - Stock Titan
Amarin announces ADS ratio change to meet Nasdaq requirements - Investing.com
Major Shake-up: Investment Firm Leader Joins Amarin Board to Drive Shareholder Value - Stock Titan
Amarin adds investment expert Michael Torok to Board By Investing.com - Investing.com
Upcoming Stock Splits This Week (April 7 to April 11) – Stay Invested - markets.businessinsider.com
A Look at New Gold Inc (NGD) Shares in the Recent Past Indicates Growth - Sete News
Breakthrough: EPA Treatment Shows Double Impact on Heart Disease When Combined with Popular Diabetes Drug - Stock Titan
Amarin announces board member departure ahead of annual meeting - Investing.com
European Equities Traded in the US as American Depositary Receipts Higher in Monday Trading - TradingView
European Equities Traded in the US as American Depositary Receipts Track Lower in Wednesday Trading - TradingView
Amarin urged to review strategy by major shareholders - Investing.com
Assessing the Risk and Potential of Sempra’s (SRE) Stock - The News Heater
Amarin Corporation plc (NASDAQ:AMRN) Q4 2024 Earnings Call Transcript - Insider Monkey
Amarin Corp PLC (AMRN) Q4 2024 Earnings Call Highlights: Navigating Challenges and Expanding ... - Yahoo Finance
Amarin Plc (AMRN) Q4 2024 Earnings Call Transcript - The Motley Fool
Amarin announce splan to initiate ratio change under ADR program - TipRanks
Amarin Announces Plan to Initiate a Ratio Change Under Its American Depository Receipt (ADR) Program - The Manila Times
Amarin Corp. (AMRN) Announces 1-For-20 ADS Ratio Change to Maintain Nasdaq Listing - StreetInsider.com
Amarin Plans Major ADR Restructuring: What This 1:20 Ratio Change Means for Investors - StockTitan
How Amarin's Latest European Reimbursement Victory Strengthens Its Cardiovascular Market Position - Stock Titan
Will Amarin's Q4 Earnings Mark a Turning Point? Key Date and Details Revealed - Stock Titan
Amarin Corp ADR (AMRN) Clearly Signals Buy-Into the Stock: Don’t ignore the signals - SETE News
European Equities Traded in the US as American Depositary Receipts Tread Water in Wednesday Trading - TradingView
Amarin Corp ADR [AMRN] Stock bought by Insider Berg Aaron for $0.1 million - Knox Daily
Ratios Uncovered: Breaking Down Amarin Corp ADR (AMRN)’s Trailing Twelve Months Metrics - The Dwinnex
Checking in on Indivior Plc (INDV) after recent insiders movement - Knox Daily
Ratios Uncovered: Breaking Down Neuronetics Inc (STIM)’s Trailing Twelve Months Metrics - The Dwinnex
Are Smart Investors Making the Right Decision? Amarin Corp ADR (AMRN) - SETE News
Views of Wall Street’s Leading Experts on SciSparc Ltd - SETE News
Stocks of Talen Energy Corp (TLN) are poised to climb above their peers - SETE News
Scholar Rock Holding Corp (SRRK) requires closer examination - US Post News
Amarin Corp ADR (AMRN) shows promising results - US Post News
Amarin Corp Adr Stock (AMRN) Financials Data
Revenue
Net Income
Cash Flow
EPS
7.33%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):